Please login to the form below

Not currently logged in
Email:
Password:

lung disease

This page shows the latest lung disease news and features for those working in and with pharma, biotech and healthcare.

MSD withdraws Keytruda’s US indication for small cell lung cancer

MSD withdraws Keytruda’s US indication for small cell lung cancer

disease, including small cell lung cancer, access new treatments,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. ... Keytruda remains a foundational treatment for

Latest news

More from news
Approximately 4 fully matching, plus 118 partially matching documents found.

Latest Intelligence

  • Addressing the payer-regulator evidence gap in early-stage cancer Addressing the payer-regulator evidence gap in early-stage cancer

    complications of disease whether measured symptomatically, radiographically, and increasingly with novel measurement techniques. ... endpoints that can better characterise the benefit of new drugs for early disease.

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    The lexicon of lung disease has been developing over four centuries from its early livid descriptions such as turgid, voluminous and catarrh coined by physicians navigating various airflow restrictions now known ... COPD was a Cinderella disease when I

  • #OrkambiNow? #OrkambiNow?

    People with this genetically inherited disease are vulnerable to potentially deadly lung infections, and currently half the people in the UK with CF die before the age of 31. ... died from the disease who might have lived had they received the drug.

  • Significant figures Significant figures

    ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... However, Insmed

  • Pharma deals during August 2014 Pharma deals during August 2014

    It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease. ... This should reduce procedure time and stimulation-induced side effects and has utility in conditions such as Parkinson's disease and essential tremor.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics